A review of Therapeutic Use of Psilocybin: Practical Considerations for Dosing and Administration

MacCallum, C. A., Lo, L. A., Pistawka, C. A., & Deol, J. K. (2022). Therapeutic use of psilocybin: Practical considerations for dosing and administration. Frontiers in Psychiatry, 13, 1040217.

Practical considerations for psilocybin are becoming increasingly important as scientific research and public interest continue to grow. As attention increases, so does confusion around psilocybin dosing, potency, and safety, especially when translating clinical research into real-world use. This article reviews key findings from MacCallum et al. (2022) and expands on them with practical insights relevant to naturally occurring psilocybin sources, including magic truffles.

What is psilocybin?

Psilocybin is an indole alkaloid, and the primary psychedelic compound found in certain mushrooms and truffles. In simple terms, this means it is a naturally occurring molecule with a specific chemical ring structure.

More importantly, psilocybin is structurally similar to serotonin, a neurotransmitter involved in mood, perception, and emotional processing. Because of this similarity, psilocybin has a strong binding affinity for the 5-HT2A receptor, which is widely understood to play a central role in psychedelic experiences.

Once ingested, psilocybin is converted in the body into psilocin, the compound responsible for the direct psychoactive effects.

Psilocybin dosing in research settings

In clinical research, psilocybin dosing has historically been approached in two main ways.

1. Weight-based dosing

Many early trials used body-weight-based dosing, typically in the range of:

0.2–0.4 mg of psilocybin per kilogram of body weight

This approach aims to standardise intensity across participants. However, individual sensitivity to psychedelics varies widely, which can still lead to differences in subjective experience.

2. Fixed dosing (the modern standard)

More recent clinical studies use a fixed dose of 25 mg of synthetic psilocybin, regardless of body weight. This dose is commonly described as producing a full psychedelic experience for most participants.

For context:

  • 25 mg of psilocybin ≈ 2.5 g of dried Psilocybe cubensis mushrooms
  • This assumes an average potency of ~1% psilocybin per gram

Potency, however, can vary significantly … more on this below.

To put these research doses into a more practical context, it helps to look at real-world equivalents.

Understanding dose ranges (real-world equivalents)

Using the common assumption of approximately 1% psilocybin per gram of dried Psilocybe cubensis, dose ranges are often described as follows:

  • Moderate dose:
    ~25 mg psilocybin ≈ 2.5 g dried mushrooms
  • High dose:
    ~35 mg psilocybin ≈ 3.5 g dried mushrooms
  • Very high or “heroic” dose:
    ~50–60 mg psilocybin ≈ 5–6 g dried mushrooms

See some of our best selling grow kits to grow your own cubensis mushrooms at home:

Important note on potency

While much of the available research and dose comparisons are based on dried psychedelic mushrooms, magic truffles are the most commonly used and legally available form of psilocybin in the Netherlands.

Because magic truffles are typically consumed fresh rather than dried, their psilocybin concentration is lower by weight. However, when adjusted for water content, comparable psychedelic effects can be achieved using higher gram amounts.

Magic truffles can differ in their natural ratio of psilocybin to psilocin, depending on species, genetics, and cultivation conditions. This ratio may influence the onset, intensity, and overall character of the experience.

Available laboratory data suggests that fresh magic truffles generally contain approximately 0.05–0.3% psilocybin per gram. Potency can vary significantly depending on species, growing conditions, freshness, and batch-to-batch variation. Because truffles are a natural biological product, it is not possible to determine the exact psilocybin content of an individual truffle or packet. This natural variability reinforces the importance of conservative dosing and gradual exploration.

Beyond dosing and potency, safety considerations also include how psilocybin interacts with other substances.

Microdose Bros stocks a range of carefully cultivated magic truffles known for their introspective and reflective qualities, see our range:

Psilocybin and medication interactions

One of the most important safety considerations highlighted by MacCallum et al. is the interaction between psilocybin and psychotropic medications, particularly those that affect the serotonin system.

Why this matters

Psilocybin acts primarily on serotonin receptors. Many psychiatric medications do the same. Combining serotonergic substances can:

  • Alter the intensity of the experience
  • Increase the risk of adverse effects
  • In rare cases, contribute to serotonin syndrome

Antidepressants and psilocybin: what we know so far

Tricyclic antidepressants (TCAs)

Some evidence suggests that tricyclic antidepressants may increase the intensity of a psychedelic experience.

Examples include:

  • Amitriptyline
  • Nortriptyline (Pamelor)
  • Imipramine (Tofranil)
  • Doxepin
  • Clomipramine (Anafranil)

These medications are also sometimes prescribed for chronic pain, migraines, insomnia, and OCD. Because TCAs affect multiple neurotransmitter systems, interactions may be unpredictable.

SSRIs and MAOIs

SSRIs (Selective Serotonin Reuptake Inhibitors) and MAOIs (Monoamine Oxidase Inhibitors) are commonly reported to blunt or dampen the effects of psilocybin.

Examples include:

  • Sertraline (Zoloft)
  • Fluoxetine (Prozac)
  • Escitalopram (Lexapro)
  • Citalopram (Celexa)
  • Paroxetine (Paxil)
  • Fluvoxamine (Luvox)

These medications are frequently prescribed for depression, anxiety disorders, panic disorder, OCD, and PTSD. Blunting does not mean no effect, but many users report reduced intensity, fewer visuals, or a more muted emotional response.

Serotonin syndrome: a key safety concern

The main theoretical risk when combining psilocybin with serotonergic medications is serotonin syndrome, a condition caused by excessive serotonin activity in the nervous system.

Symptoms can range from mild to severe:

  • Mild: shivering, sweating, diarrhea
  • Moderate: agitation, increased heart rate, tremor
  • Severe: high fever, muscle rigidity, confusion, rapid heartbeat

Current research suggests serotonin syndrome is rare, but:

  • Individual sensitivity varies
  • Research is still limited
  • Risk depends on dose, combinations, and personal physiology

This is an area where more data is needed, and caution is always advised.

Additional practical considerations (beyond the paper)

Set, setting, and preparation matter

Clinical trials consistently emphasise the importance of preparation, intention-setting, and a supportive environment. These factors can have as much influence on the experience as dose itself.

Consider:

  • Mental state before the experience
  • Physical comfort and safety
  • A calm, familiar environment
  • Time afterward for rest and integration

Start lower than you think

Due to natural potency variation and individual sensitivity, starting conservatively is almost always wise. While you cannot undo a high dose, you can gradually build over time. This applies whether someone is microdosing, macrodosing, or exploring deeper experiences.

Integration is part of the process

Clinical studies highlight integration—reflecting on and applying insights after the experience—as essential for long-term benefit. Journaling, meditation, gentle movement, or open conversation can help translate insights into everyday life.

Practical Considerations Key Takeaways

  • Psilocybin dosing in research is standardized; real-world potency is not
  • Natural variability is unavoidable with mushrooms and truffles
  • Truffles require different dosing logic due to water content
  • Medication interactions matter and require caution
  • Preparation and integration are as important as dose

Follow Microdose Bros

Stay connected with Microdose Bros for educational content, product updates, and insights on plant medicine, microdosing, and emotional wellbeing.